About
CureTech is a biotechnology company developing broad-spectrum, immune-modulating products for the treatment and control of cancer. Its product line includes antibodies and peptide-based vaccines designed to modulate the immune response, allowing it to exert its anti-cancer activity in an effective manner. CureTech's lead humanized antibody product, pidilizumab (CT-011), is in Phase II clinical testing. Pidilizumab has shown promising results in attenuating tumor growth and eliminating tumor metastases in a variety of model systems. Several patents and pending patent applications worldwide protect the company's products. A licensing agreement for further development and commercialization of pidilizumab was signed with Medivation in 2014. In 2018, InSight Innovations acquired CureTech.
Funding history · 1 round · $4.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is CureTech's primary focus?
- CureTech is a biotechnology company specializing in developing broad-spectrum, immune-modulating products for cancer treatment and control, including antibodies and peptide-based vaccines.
- What is the status of CureTech's lead product, pidilizumab (CT-011)?
- CureTech's lead humanized antibody product, pidilizumab (CT-011), is in Phase II clinical testing and has shown promising results in attenuating tumor growth and eliminating tumor metastases in various model systems.
- When did CureTech sign a licensing agreement for pidilizumab?
- In 2014, CureTech signed a licensing agreement with Medivation for the further development and commercialization of pidilizumab.
- When was CureTech acquired and by whom?
- CureTech was acquired by InSight Innovations in 2018.
- What was the outcome of the acquisition deal with InSight Innovations in July 2018?
- In July 2018, following the cancellation of the acquisition deal with InSight Innovations, CureTech implemented cost-cutting measures.
- When did CureTech cease operations?
- CureTech ceased to operate in February 2019, becoming an inactive company.
- What was the total amount of funding raised by CureTech?
- CureTech raised a total of $4,000,000 in funding. For a full financing history, please refer to startupim.
- Who was an investor in CureTech's September 2013 funding round?
- Clal Biotechnology Industries (CBI) was an investor in CureTech's undisclosed funding round in September 2013.
- What was the reported status of CureTech in February 2020?
- According to a February 2020 news report, CureTech's cancer-fighting dreams ended with insolvency.